<p>AnaptysBio, Inc.（纳斯达克代码：ANAB - 获取免费报告）在周四的午盘交易中达到了新的 52 周高点。该股最高交易价为 48.35 美元，最后交易价为 47.89 美元，成交量为 251891 股。该股此前收盘价为 45.69 美元。</p>
<h2>分析师评级调整</h2>
<ul>
<li>Argenx 股价上涨 28% 及其有前景的产品提升了投资者信心</li>
</ul>
<p>几位分析师最近对该股票发表了评论。富国银行将 AnaptysBio 的目标股价从 51.00 美元上调至 81.00 美元，并在 11 月 5 日的报告中给予该公司 “增持” 评级。Truist Financial 将 AnaptysBio 的目标股价从 20.00 美元上调至 36.00 美元，并在 11 月 10 日的报告中给予该股 “持有” 评级。巴克莱将 AnaptysBio 的目标股价从 70.00 美元下调至 55.00 美元，并在周三的研究报告中为该公司设定了 “增持” 评级。古根海姆在周四的研究报告中重申了对 AnaptysBio 的 “买入” 评级。最后，华尔街 Zen 在 11 月 16 日的研究报告中将 AnaptysBio 的评级从 “买入” 上调至 “强力买入”。一位分析师给予该股 “强力买入” 评级，八位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股的平均评级为 “适度买入”，共识目标价为 55.40 美元。</p>
<p><strong>阅读我们对 AnaptysBio 的最新股票分析</strong></p>
<h2>AnaptysBio 价格表现</h2>
<p>该公司的市值为 13.2 亿美元，市盈率为-16.85，贝塔值为 0.29。该公司的 50 日简单移动平均线为 38.13 美元，200 日简单移动平均线为 28.60 美元。</p>
<p>AnaptysBio（纳斯达克代码：ANAB - 获取免费报告）最近在 11 月 4 日宣布了其季度财报。这家生物技术公司报告季度每股收益为 0.52 美元，超出分析师一致预期的-1.06 美元，超出幅度为 1.58 美元。该季度的营业收入为 7632 万美元，而分析师预期为 1583 万美元。AnaptysBio 的股本回报率为-1101.24%，净利润率为-49.94%。作为一个整体，股票研究分析师预测 AnaptysBio, Inc.在本年度将发布-6.08 美元的每股收益。</p>
<p>AnaptysBio 宣布其董事会已于 11 月 21 日批准了一项股票回购计划，允许公司回购 1 亿美元的流通股。该回购授权允许这家生物技术公司通过公开市场购买回购最多 9.6% 的股份。股票回购计划通常表明公司的领导层认为其股票被低估。</p>
<h2>内部人士下注</h2>
<p>在其他 AnaptysBio 的新闻中，内部人士 Eric J. Loumeau 于 12 月 17 日星期三出售了 10,000 股该股票。股票以平均价格 46.00 美元出售，总交易额为 460,000.00 美元。出售完成后，该内部人士持有 9088 股公司股票，价值 418,048 美元。这代表其持股减少了 52.39%。该交易在向 SEC 的备案中披露，相关信息可在 SEC 网站上查阅。此外，首席财务官 Dennis Mulroy 于 12 月 16 日星期二出售了 15,725 股公司的股票。该股票以平均价格 44.85 美元出售，总交易额为 705,266.25 美元。出售完成后，首席财务官直接持有公司 9,401 股，价值约 421,634.85 美元。该交易代表其持股减少了 62.58%。该交易的披露信息可在 SEC 备案中找到。在过去一个季度，内部人士共出售了 38,366 股公司股票，价值 1,732,642 美元。目前，33.50% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 AnaptysBio 的看法</h2>
<p>大型投资者最近对该公司的持股进行了调整。First Light Asset Management LLC 在第一季度将其在 AnaptysBio 的持股增加了 433.3%。First Light Asset Management LLC 现在拥有 4633602 股该生物技术公司的股票，价值 86139000 美元，在此期间又增持了 3764720 股。Assenagon Asset Management S.A.在第三季度将其在 AnaptysBio 的持股增加了 4852.7%。Assenagon Asset Management S.A.现在拥有 839934 股该生物技术公司的股票，价值 25719000 美元，在上个季度又购买了 822975 股。Caption Management LLC 在第一季度将其在 AnaptysBio 的持股增加了 106.3%。Caption Management LLC 现在拥有 23376 股该生物技术公司的股票，价值 435000 美元，在此期间又增持了 394634 股。Woodline Partners LP 在第一季度将其在 AnaptysBio 的持股增加了 63.1%。Woodline Partners LP 现在拥有 791023 股该生物技术公司的股票，价值 14705000 美元，在上个季度又增持了 305950 股。最后，683 Capital Management LLC 在第二季度将其在 AnaptysBio 的持股增加了 155.6%。683 Capital Management LLC 现在拥有 500000 股该生物技术公司的股票，价值 11100000 美元，在此期间又增持了 304373 股。</p>
<h2>关于 AnaptysBio</h2>
<p>（获取免费报告）</p>
<p>AnaptysBio, Inc.是一家临床阶段的生物技术公司，专注于提供免疫治疗药物。其产品包括 Rosnilimab，一种针对 PD-1+ T 细胞的 IgG1 抗体，能够激活或消耗这些细胞，广泛影响自身免疫和炎症疾病的致病驱动因素；ANB032，一种非消耗性抗体，能够结合 BTLA 检查点受体并抑制活化 T 细胞的增殖；ANB033，一种新型抗 CD122 拮抗抗体，针对 IL-15 和 IL-2 受体的共享共同β亚基；ANB101，一种 BDCA2 调节抗体，专门针对浆细胞样树突细胞（pDCs）；以及 Imsidolimab，一种抑制白细胞介素-36 受体的抗体，目前正在进行针对广泛性脓疱性银屑病的三期开发。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比 AnaptysBio 更好的股票</li>
<li>股票行业对成功投资的重要性是什么？</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>低市盈率成长股：解锁投资机会</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>什么是认沽期权成交量？</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 AnaptysBio 吗？</h2>
<p>在你考虑 AnaptysBio 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 AnaptysBio 并不在名单上。</p>
<p>虽然 AnaptysBio 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ANAB

<p>AnaptysBio（纳斯达克代码：ANAB）达到了新的 52 周高点，交易价格为 48.35 美元。分析师的评级各不相同，富国银行将目标价格上调至 81.00 美元，而巴克莱则将其下调至 55.00 美元。该公司宣布了一项 1 亿美元的股票回购计划，表明其被低估。内部人士出售了股份，而机构投资者则显著增加了持股。该股票的平均评级为 “适度买入”，共识目标价格为 55.40 美元</p>

<p>AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $48.35 and last traded at $47.89, with a volume of 251891 shares. The stock had previously closed at $45.69.</p>
<div class="lb-trans"><p>AnaptysBio, Inc.（纳斯达克代码：ANAB - 获取免费报告）在周四的午盘交易中达到了新的 52 周高点。该股最高交易价为 48.35 美元，最后交易价为 47.89 美元，成交量为 251891 股。该股此前收盘价为 45.69 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 股价上涨 28% 及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>Several analysts have recently commented on the stock. Wells Fargo &amp; Company increased their target price on shares of AnaptysBio from $51.00 to $81.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, November 5th. Truist Financial raised their price objective on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a &#34;hold&#34; rating in a report on Monday, November 10th. Barclays decreased their price target on shares of AnaptysBio from $70.00 to $55.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday. Guggenheim reiterated a &#34;buy&#34; rating on shares of AnaptysBio in a research note on Thursday. Finally, Wall Street Zen upgraded AnaptysBio from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $55.40.</p>
<div class="lb-trans"><p>几位分析师最近对该股票发表了评论。富国银行将 AnaptysBio 的目标股价从 51.00 美元上调至 81.00 美元，并在 11 月 5 日的报告中给予该公司 “增持” 评级。Truist Financial 将 AnaptysBio 的目标股价从 20.00 美元上调至 36.00 美元，并在 11 月 10 日的报告中给予该股 “持有” 评级。巴克莱将 AnaptysBio 的目标股价从 70.00 美元下调至 55.00 美元，并在周三的研究报告中为该公司设定了 “增持” 评级。古根海姆在周四的研究报告中重申了对 AnaptysBio 的 “买入” 评级。最后，华尔街 Zen 在 11 月 16 日的研究报告中将 AnaptysBio 的评级从 “买入” 上调至 “强力买入”。一位分析师给予该股 “强力买入” 评级，八位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股的平均评级为 “适度买入”，共识目标价为 55.40 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on AnaptysBio</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 AnaptysBio 的最新股票分析</strong></p>
</div><h2>AnaptysBio Price Performance</h2>
<div class="lb-trans"><h2>AnaptysBio 价格表现</h2>
</div><p>The firm has a market capitalization of $1.32 billion, a P/E ratio of -16.85 and a beta of 0.29. The firm's 50 day simple moving average is $38.13 and its two-hundred day simple moving average is $28.60.</p>
<div class="lb-trans"><p>该公司的市值为 13.2 亿美元，市盈率为-16.85，贝塔值为 0.29。该公司的 50 日简单移动平均线为 38.13 美元，200 日简单移动平均线为 28.60 美元。</p>
</div><p>AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million for the quarter, compared to analysts' expectations of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. As a group, equities research analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current year.</p>
<div class="lb-trans"><p>AnaptysBio（纳斯达克代码：ANAB - 获取免费报告）最近在 11 月 4 日宣布了其季度财报。这家生物技术公司报告季度每股收益为 0.52 美元，超出分析师一致预期的-1.06 美元，超出幅度为 1.58 美元。该季度的营业收入为 7632 万美元，而分析师预期为 1583 万美元。AnaptysBio 的股本回报率为-1101.24%，净利润率为-49.94%。作为一个整体，股票研究分析师预测 AnaptysBio, Inc.在本年度将发布-6.08 美元的每股收益。</p>
</div><p>AnaptysBio declared that its Board of Directors has approved a stock repurchase program on Friday, November 21st that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's leadership believes its shares are undervalued.</p>
<div class="lb-trans"><p>AnaptysBio 宣布其董事会已于 11 月 21 日批准了一项股票回购计划，允许公司回购 1 亿美元的流通股。该回购授权允许这家生物技术公司通过公开市场购买回购最多 9.6% 的股份。股票回购计划通常表明公司的领导层认为其股票被低估。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other AnaptysBio news, insider Eric J. Loumeau sold 10,000 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $46.00, for a total transaction of $460,000.00. Following the completion of the sale, the insider owned 9,088 shares of the company's stock, valued at $418,048. This represents a 52.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Dennis Mulroy sold 15,725 shares of the firm's stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $44.85, for a total transaction of $705,266.25. Following the completion of the sale, the chief financial officer directly owned 9,401 shares in the company, valued at approximately $421,634.85. This trade represents a 62.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 38,366 shares of company stock valued at $1,732,642 over the last quarter. 33.50% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 AnaptysBio 的新闻中，内部人士 Eric J. Loumeau 于 12 月 17 日星期三出售了 10,000 股该股票。股票以平均价格 46.00 美元出售，总交易额为 460,000.00 美元。出售完成后，该内部人士持有 9088 股公司股票，价值 418,048 美元。这代表其持股减少了 52.39%。该交易在向 SEC 的备案中披露，相关信息可在 SEC 网站上查阅。此外，首席财务官 Dennis Mulroy 于 12 月 16 日星期二出售了 15,725 股公司的股票。该股票以平均价格 44.85 美元出售，总交易额为 705,266.25 美元。出售完成后，首席财务官直接持有公司 9,401 股，价值约 421,634.85 美元。该交易代表其持股减少了 62.58%。该交易的披露信息可在 SEC 备案中找到。在过去一个季度，内部人士共出售了 38,366 股公司股票，价值 1,732,642 美元。目前，33.50% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On AnaptysBio</h2>
<div class="lb-trans"><h2>机构投资者对 AnaptysBio 的看法</h2>
</div><p>Large investors have recently made changes to their positions in the business. First Light Asset Management LLC grew its holdings in shares of AnaptysBio by 433.3% during the 1st quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company's stock worth $86,139,000 after acquiring an additional 3,764,720 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of AnaptysBio by 4,852.7% during the third quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company's stock valued at $25,719,000 after purchasing an additional 822,975 shares in the last quarter. Caption Management LLC grew its stake in AnaptysBio by 106.3% in the first quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company's stock worth $435,000 after purchasing an additional 394,634 shares during the period. Woodline Partners LP raised its holdings in AnaptysBio by 63.1% in the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company's stock worth $14,705,000 after purchasing an additional 305,950 shares in the last quarter. Finally, 683 Capital Management LLC lifted its position in AnaptysBio by 155.6% during the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company's stock valued at $11,100,000 after buying an additional 304,373 shares during the period.</p>
<div class="lb-trans"><p>大型投资者最近对该公司的持股进行了调整。First Light Asset Management LLC 在第一季度将其在 AnaptysBio 的持股增加了 433.3%。First Light Asset Management LLC 现在拥有 4633602 股该生物技术公司的股票，价值 86139000 美元，在此期间又增持了 3764720 股。Assenagon Asset Management S.A.在第三季度将其在 AnaptysBio 的持股增加了 4852.7%。Assenagon Asset Management S.A.现在拥有 839934 股该生物技术公司的股票，价值 25719000 美元，在上个季度又购买了 822975 股。Caption Management LLC 在第一季度将其在 AnaptysBio 的持股增加了 106.3%。Caption Management LLC 现在拥有 23376 股该生物技术公司的股票，价值 435000 美元，在此期间又增持了 394634 股。Woodline Partners LP 在第一季度将其在 AnaptysBio 的持股增加了 63.1%。Woodline Partners LP 现在拥有 791023 股该生物技术公司的股票，价值 14705000 美元，在上个季度又增持了 305950 股。最后，683 Capital Management LLC 在第二季度将其在 AnaptysBio 的持股增加了 155.6%。683 Capital Management LLC 现在拥有 500000 股该生物技术公司的股票，价值 11100000 美元，在此期间又增持了 304373 股。</p>
</div><h2>About AnaptysBio</h2>
<div class="lb-trans"><h2>关于 AnaptysBio</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.</p>
<div class="lb-trans"><p>AnaptysBio, Inc.是一家临床阶段的生物技术公司，专注于提供免疫治疗药物。其产品包括 Rosnilimab，一种针对 PD-1+ T 细胞的 IgG1 抗体，能够激活或消耗这些细胞，广泛影响自身免疫和炎症疾病的致病驱动因素；ANB032，一种非消耗性抗体，能够结合 BTLA 检查点受体并抑制活化 T 细胞的增殖；ANB033，一种新型抗 CD122 拮抗抗体，针对 IL-15 和 IL-2 受体的共享共同β亚基；ANB101，一种 BDCA2 调节抗体，专门针对浆细胞样树突细胞（pDCs）；以及 Imsidolimab，一种抑制白细胞介素-36 受体的抗体，目前正在进行针对广泛性脓疱性银屑病的三期开发。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than AnaptysBio</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>What is Put Option Volume?</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 AnaptysBio 更好的股票</li>
<li>股票行业对成功投资的重要性是什么？</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>低市盈率成长股：解锁投资机会</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>什么是认沽期权成交量？</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AnaptysBio Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 AnaptysBio 吗？</h2>
</div><p>Before you consider AnaptysBio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 AnaptysBio 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 AnaptysBio 并不在名单上。</p>
</div><p>While AnaptysBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 AnaptysBio 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

AnaptysBio（NASDAQ:ANAB）创下一年新高 - 接下来会如何发展？